Modalis Therapeutics (TSE:4883) Buyback Yield %: -42.91 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円34.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics Buyback Yield %?

Modalis Therapeutics TSE:4883 20 Buyback Yield % is -42.91 as of Jul. 17, 2026. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 291 Drug Manufacturers companies, Modalis Therapeutics ranks worse than 93.47% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Modalis Therapeutics's current buyback yield was -42.91%.

Modalis Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Buyback Yield % Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -0.41 -0.62 -17.80 -33.68 -28.11

Modalis Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -28.11 0.00

TSE:4883 vs ZTS, UTHR: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modalis Therapeutics Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's Buyback Yield % falls into.


TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modalis Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Modalis Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 1364.154) / 4853.744
=-28.11%

Modalis Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1364.154) / 4853.744
=-28.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -42.91 mean?
Modalis Therapeutics (TSE:4883) has a Buyback Yield % of -42.91 as of Jul. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Modalis Therapeutics and its competitors. According to the industry distribution chart, Modalis Therapeutics ranks #272 out of 291 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Modalis Therapeutics' Buyback Yield % too high?
Modalis Therapeutics' current Buyback Yield % is -42.91. Based on the distribution chart, Modalis Therapeutics ranks #272 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #272 out of 291 companies for Buyback Yield %. This places Modalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Modalis Therapeutics and its competitors. Modalis Therapeutics's current Buyback Yield % is -42.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Buyback Yield % of -42.91. The current Buyback Yield % is -42.91. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Buyback Yield % is -42.91 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円34.00
Price